New Jersey- New York Multiple Myeloma Rounds
BiTE Molecules: A New Treatment in Relapsed Myeloma Population
How to Optimize Therapy in Elderly/Frail Patients with Multiple Myeloma
Divaya Bhutani, MD
Divaya Bhutani, MD is the Clinical Director of Multiple Myeloma and Amyloidosis program at Columbia University Medical Center, New York. His primary research interests includes new drug development for patients with plasma cell disorders as well as development of new treatment strategies for patients with Monoclonal Gammopathy of Renal Significance.
Malin Hultcrantz, MD, PhD
Malin Hultcrantz, MD, PhD is a board-certified Hematologist at Memorial Sloan Kettering Cancer Center. She completed her residency in Internal Medicine at the Orebro University Hospital in Sweden. Dr. Hultcranz completed her Hematology/Internal Medicine fellowship at Karolinska University Hospital and her Advanced Oncology Fellowship at Memorial Sloan Kettering Cancer Center. She won the Multiple Myeloma Research Foundation Research Fellow Award in 2015.
James Hoffman, MD
James Hoffman, MD is a board certified hematology oncologist. He completed his undergraduate studies at Columbia University and attended medical school at Albert Einstein College of Medicine in New York.
Dr. Hoffman completed his internship and residency program in Internal Medicine, and served as Chief Medical Resident at New York University Medical Center. Dr. Hoffman is a Memorial Sloan-Kettering Cancer Center trained fellow specializing in medical oncology and hematology with a focus on plasma cell diseases including multiple myeloma and amyloidosis.
Prior to joining the Sylvester Cancer Center, Dr. Hoffman served as a faculty member in the hematology-oncology division at the Cleveland Clinic in Florida where he was director of the clinical lab.
He is now Director of the Myeloma and Amyloidosis site disease group and Associate Director of the Hematology/Oncology Fellowship Program at Sylvester.
C. Ola Landgren, MD, PhD (Moderator)
C. Ola Landgren, MD, PhD is a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring by new minimal residual disease (MRD) assays, as well as biological studies focusing on disease and host biology. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. He has a strong interest in the development of early-treatment clinical trials targeting high-risk smoldering myeloma.
Dr. Landgren is one of the pioneers in the development of MRD testing in myeloma. In collaboration with colleagues at MSK as well nationally/internationally, he develops new strategies (including cell-based, molecular-based, and imaging-based) and implement advanced MRD testing in clinical trials at MSK. He is involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients.
In addition, Dr. Landgren leads the development of a structured program for the education and mentoring of residents and fellows in the Myeloma Service. The service also takes part in regular multi-disciplinary clinical conferences and scientific meetings. He is also fluent in English, Swedish and German.
Suzanne Lentzsch, MD, PhD (Moderator)
Dr. Lentzsch is a Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ CharitÃ© Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA.
Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia.
Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.
Deepu Madduri, MD
Deepu Madduri, MD is Assistant Professor of Medicine (Hematology and Medical Oncology). She is Associate Director, Cellular Therapy Service, and Director of Clinical Operations with the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai. Dr. Madduri specializes in plasma cell disorders including multiple myeloma, amyloid light-chain amyloidosis, POEMS syndrome, plasmacytoma, and monoclonal gammopathies of uncertain significance. She performs a variety of procedures including bone marrow biopsies and stem cell transplant. She serves as the lead physician liaison between the Center of Excellence for Multiple Myeloma and the Bone Marrow and Stem Cell Transplantation Program at The Mount Sinai Hospital.
Dr. Madduri’s research focuses on the clinical management of plasma cell dyscrasias with a strong emphasis on relapsed and refractory multiple myeloma. Her research has included first-in-human/phase 1 clinical trial studies ranging from immunotherapy with checkpoint inhibitors and immune effector cells such as CAR T-cell therapy, NK-cell therapy, and Bi-specific antibodies. She has played an integral role in initiating CAR T-cell studies for myeloma. She is also a member of the Clinical Research Services team for cellular therapies at Mount Sinai and a member of the Bone Marrow Transplant Clinical Trials Network protocol committee.
Dr. Madduri received her MD from the College of Medicine at the University of Oklahoma. She completed her residency in Internal Medicine at St. Mary Medical Center in Langhorne, Pennsylvania, and a fellowship in Hematology and Oncology at the University of California, Harbor Campus in Torrance, California, with additional fellowship training in Blood and Marrow Transplant at Stanford Hospital. Dr. Madduri serves as an oncology consultant at Foundation Medicine, Inc., a cancer genomic company, and leads their Smart Trials Precision enrollment program.